• Vaccine Name: Trovac-AI-H5
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Tradename: Trovac AI H5
• Manufacturer: Merial
• Vaccine Ontology ID: VO_0000839
• Type: Recombinant vector vaccine
• Status: Licensed
• Host Species for Licensed Use: Pig
• HA gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001040
• Preparation: Different vaccines expressing the haemagglutinin of a highly pathogenic (HP) H5N1 avian influenza virus (AIV) (A/chicken/Indonesia/7/03) (Kyriakis et al., 2009).
• Immunization Route: Intramuscular injection (i.m.)
• Description: Fowlpox virus-vectored H5 (Bublot et al., 2006)

Pig Response

• Vaccination Protocol: Pigs were vaccinated twice, with a 4-week interval, with a fowlpox (TROVAC), a canarypox (ALVAC), or a vaccinia (NYVAC) vector vaccine combined with an oil-in-water adjuvant, with the unadjuvanted NYVAC, or left unvaccinated (Kyriakis et al., 2009).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Six weeks after the second vaccination, all pigs were challenged intra-tracheally with low pathogenic (LP) H5N2 AIV A/chicken/Belgium/150/99 (Kyriakis et al., 2009).
• Efficacy: The NYVAC and ALVAC adjuvanted vaccines consistently induced higher antibody titres than TROVAC or NYVAC without adjuvant. Following challenge, the H5N2 challenge virus was isolated from all unvaccinated pigs, while 19 out of 21 vaccinates showed complete virological protection. Pox-vector vaccines were safe, immunogenic and efficacious against challenge with a heterologous H5 AIV, offering an alternative to classical inactivated vaccines (Kyriakis et al., 2009).